Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2019-03-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
关于控股股东同业竞争承诺事项履行完毕的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jinling Pharmaceutical Co., Ltd. regarding the fulfillment of commitments made by its controlling shareholder to resolve conflicts of interest related to competition within the same industry. It details changes in shareholding and control over related companies, indicating the completion of certain restructuring and share transfers. The document is short (1280 characters) and serves as a formal disclosure of a specific corporate governance matter rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report publication announcement since it contains substantive information about the shareholder commitments and their fulfillment. The content fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2019-03-25 Chinese
2018年度监事会工作报告
Audit Report / Information Classification · 90% confidence The document is titled as the "2018 Annual Supervisory Board Work Report" of Jinling Pharmaceutical Co., Ltd. It details the activities and opinions of the supervisory board during the 2018 fiscal year, including meetings held, oversight of financial management, internal controls, related party transactions, and plans for 2019. The content is a detailed report on the supervisory board's work and opinions rather than an announcement or a brief summary. It does not fit categories like Annual Report (10-K) or Interim Report (IR) because it focuses on supervisory board activities and oversight rather than full financial statements or management discussion. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains substantive content rather than just a notice. The document aligns best with Audit Report / Information (AR) as it includes audit opinions and supervisory board oversight related to financial and internal control matters, which is typical for audit-related reports distinct from full annual reports. FY 2018
2019-03-25 Chinese
2018年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as the 2018 annual financial settlement report of Jinling Pharmaceutical Co., Ltd. It includes detailed financial statements, analysis of assets, liabilities, equity, income, expenses, and profit for the year 2018. It also references an audit report issued by Tianheng Accounting Firm, indicating the financial statements have been audited. The content covers comprehensive financial data for the full fiscal year 2018, including changes in accounting policies, consolidated subsidiaries, and detailed financial metrics. The length of the document (8093 characters) and the depth of financial data confirm it is a full annual report rather than a brief announcement or certification. Therefore, the document fits the definition of an Annual Report (10-K). FY 2018
2019-03-25 Chinese
关于2019年度日常关联交易预计情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the expected daily related-party transactions for the year 2019. It includes details about the nature, amounts, and pricing principles of these related-party transactions, as well as independent directors' opinions and board meeting resolutions. The document is structured as a formal announcement with no detailed financial statements or comprehensive financial analysis. It primarily serves to inform shareholders and the public about anticipated related-party transactions and the board's approval thereof. This type of document fits the category of a Regulatory Filing (RNS) because it is a regulatory disclosure about related-party transactions and board approvals, not a full annual report, audit report, or financial statement. The document length (5115 characters) and content confirm it is not a report publication announcement or a full financial report but a regulatory announcement.
2019-03-25 Chinese
第七届监事会第十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Jinling Pharmaceutical Co., Ltd. It details the convening and decisions made during the 12th meeting of the 7th Supervisory Board, including approval of the 2018 Supervisory Board Work Report, 2018 Financial Final Accounts Report, 2018 Profit Distribution Plan, Internal Control Self-Evaluation Report, and the 2018 Annual Report and its summary. The document is a formal announcement of meeting resolutions and approvals rather than the full annual report itself. It also references that the 2018 Annual Report is available on the CNINFO website, indicating this document is an announcement of decisions related to the annual report rather than the report itself. The document length is short (1609 characters), consistent with an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS) as a formal regulatory announcement of supervisory board meeting resolutions and approvals related to annual reports and other corporate governance matters.
2019-03-25 Chinese
委托理财管理办法（2019年3月）
Governance Information Classification · 95% confidence The document is titled as a management policy document for entrusted financial management by Jinling Pharmaceutical Co., Ltd. It outlines principles, operational norms, risk control, and responsibilities related to the company's entrusted financial management activities. It is a governance or internal management guideline document rather than a financial report, announcement, or regulatory filing. There is no indication of financial statements, audit results, voting results, or any other report type. The content fits best under Governance Information (CGR) as it details internal rules and management practices related to financial management.
2019-03-25 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.